ACADIA Pharmaceuticals Inc Earnings
The next earnings date for ACADIA Pharmaceuticals Inc is November 4, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of ACADIA Pharmaceuticals Inc Earnings
| 11/04/2026 | $0.21 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
ACADIA Pharmaceuticals Inc Earnings: Historical
| 08/04/2026 | After Market | $0.18 | 200.00% |
| 05/06/2026 | After Market | $0.02 | -75.00% |
| 03/02/2026 | --- | $0.14 | -1.01% |
| 11/05/2025 | After Market | $0.26 | 85.71% |
| 08/06/2025 | After Market | $0.16 | 14.29% |
| 05/07/2025 | After Market | $0.11 | 0.00% |
| 02/25/2025 | Before Market | $0.86 | 292.69% |
| 11/06/2024 | After Market | $0.20 | 42.86% |
| 08/06/2024 | After Market | $0.20 | 11.11% |
| 05/08/2024 | After Market | $0.10 | 66.67% |
More About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
“ACADIA Pharmaceuticals Inc Earnings” Can Refer to the ACADIA Pharmaceuticals Inc Earnings Date
Some people say “ACADIA Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my ACADIA Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning ACADIA Pharmaceuticals Inc Stock on the Earnings Date
If you own ACADIA Pharmaceuticals Inc stock (ACAD) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for ACADIA Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading ACADIA Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More ACADIA Pharmaceuticals Inc Earnings
You can contact us any time if you would like to ask questions about ACADIA Pharmaceuticals Inc earnings or anything else related to the stock market.